Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Average Salary Hikes in 2005 Slightly Down from 2004: Survey
August 8, 2005
- Fujifilm Subsidiary to Launch Package Insert Design Software
August 8, 2005
- Doctors' Influence on Drug Selection Is Decreasing: Mr Baba
August 8, 2005
- BUSINESS NEWS IN BRIEF
August 8, 2005
- NEW PRODUCTS
August 8, 2005
- 4th Scientific Meeting of Japan Society of Generic Medicine
August 8, 2005
- Toyama Prefecture to Establish Council to Promote GE Drug Use
August 8, 2005
- SURVEY 2 articles
August 1, 2005
- OPINION
August 1, 2005
- FPMAJ, PhRMA, and EFPIA to Struggle Arm in Arm for Reform of NHI Pricing
August 1, 2005
- 63.7% of Municipal General Hospitals Ran Deficits in FY2004
August 1, 2005
- COMMENTARY 5 articles
August 1, 2005
- Korosho's Study Group on Clinical Trials Holds 5th Meeting
August 1, 2005
- Chuikyo Needs More Public Interest Representatives: Council
August 1, 2005
- Kenporen Presents Its Own Proposal for Healthcare Reform
August 1, 2005
- Differences Between FDA and PMDA Discussed: Symposium
August 1, 2005
- REGULATORY NEWS IN BRIEF
August 1, 2005
- Tsumura Announces New 3-Year Management Plan
August 1, 2005
- Nichi-iko to Do More Business through Wholesalers, Sell More to DPC Hospitals
August 1, 2005
- Parexel Working to Expand Business in Japan
August 1, 2005
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…